- Home
- GNLX vs CRDL Comparison
GNLX vs CRDL Comparison
Compare GNLX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- CRDL
- Stock Information
- Founded
- GNLX 2001
- CRDL 2017
- Country
- GNLX United States
- CRDL Canada
- Employees
- GNLX N/A
- CRDL N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- CRDL Health Care
- Exchange
- GNLX Nasdaq
- CRDL Nasdaq
- Market Cap
- GNLX 129.9M
- CRDL 126.5M
- IPO Year
- GNLX 2023
- CRDL N/A
- Fundamental
- Price
- GNLX $3.53
- CRDL $1.48
- Analyst Decision
- GNLX Strong Buy
- CRDL Strong Buy
- Analyst Count
- GNLX 5
- CRDL 2
- Target Price
- GNLX $16.20
- CRDL $9.00
- AVG Volume (30 Days)
- GNLX 153.8K
- CRDL 365.4K
- Earning Date
- GNLX 08-13-2025
- CRDL 08-11-2025
- Dividend Yield
- GNLX N/A
- CRDL N/A
- EPS Growth
- GNLX N/A
- CRDL N/A
- EPS
- GNLX N/A
- CRDL N/A
- Revenue
- GNLX N/A
- CRDL N/A
- Revenue This Year
- GNLX N/A
- CRDL N/A
- Revenue Next Year
- GNLX N/A
- CRDL N/A
- P/E Ratio
- GNLX N/A
- CRDL N/A
- Revenue Growth
- GNLX N/A
- CRDL N/A
- 52 Week Low
- GNLX $1.60
- CRDL $0.77
- 52 Week High
- GNLX $5.89
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- GNLX 58.36
- CRDL 57.55
- Support Level
- GNLX $3.30
- CRDL $1.36
- Resistance Level
- GNLX $3.60
- CRDL $1.59
- Average True Range (ATR)
- GNLX 0.26
- CRDL 0.11
- MACD
- GNLX 0.00
- CRDL 0.02
- Stochastic Oscillator
- GNLX 75.71
- CRDL 75.56
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.